WO2012047993A3 - N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv - Google Patents

N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv Download PDF

Info

Publication number
WO2012047993A3
WO2012047993A3 PCT/US2011/054916 US2011054916W WO2012047993A3 WO 2012047993 A3 WO2012047993 A3 WO 2012047993A3 US 2011054916 W US2011054916 W US 2011054916W WO 2012047993 A3 WO2012047993 A3 WO 2012047993A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
hiv
hcv
methods
inhibitors
Prior art date
Application number
PCT/US2011/054916
Other languages
French (fr)
Other versions
WO2012047993A2 (en
Inventor
Zhengqiang Wang
Robert J. Geraghty
Robert Vince
Jinq Tang
Original Assignee
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of The University Of Minnesota filed Critical Regents Of The University Of Minnesota
Publication of WO2012047993A2 publication Critical patent/WO2012047993A2/en
Publication of WO2012047993A3 publication Critical patent/WO2012047993A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention provides antiviral compounds that can be used in therapy against human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Compounds of the invention can be dual targeted inhibitors of HIV, inhibiting both the reverse transcriptase and the integrase enzyme systems, thus increasing the barrier to development of viral resistance in patients. Prodrugs of the inventive antiviral compounds are also provided. Compounds of the invention can be used to treat HCV secondary infections in HIV-afflicted patients, reducing the need for administration of drug cocktails containing multiple, potentially conflicting, medicinal compounds. Methods of synthesis of the compounds and methods of treatment using the compounds are also provided.
PCT/US2011/054916 2010-10-05 2011-10-05 N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv WO2012047993A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38979510P 2010-10-05 2010-10-05
US61/389,795 2010-10-05

Publications (2)

Publication Number Publication Date
WO2012047993A2 WO2012047993A2 (en) 2012-04-12
WO2012047993A3 true WO2012047993A3 (en) 2012-05-31

Family

ID=45928401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/054916 WO2012047993A2 (en) 2010-10-05 2011-10-05 N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv

Country Status (1)

Country Link
WO (1) WO2012047993A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141220A1 (en) * 2015-03-03 2016-09-09 Regents Of The University Of Minnesota 3-hydroxypyrimidine-2,4-dione-5-carboxamides as potent inhibitors of hiv
EP3353154B3 (en) * 2015-09-25 2022-10-19 Ludwig Institute for Cancer Research Ltd 3-hydroxy-7-(sulfonyl)quinazoline-2,4(1h,3h)-dione and 3-hydroxy-pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives and related compounds as flap-endonuclease 1 (fen-1) inhibitors for use in cancer therapy
JPWO2023017699A1 (en) * 2021-08-12 2023-02-16

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021936A1 (en) * 1998-10-12 2000-04-20 Sumitomo Chemical Company, Limited Uracil herbicides
US20030119814A1 (en) * 2001-10-16 2003-06-26 The University Of Kansas Novel prodrugs of N-H bond-containing compounds and methods of making thereof
US20100074889A1 (en) * 2008-09-15 2010-03-25 Yao-Ling Qiu 4'-allene-substituted nucleoside derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021936A1 (en) * 1998-10-12 2000-04-20 Sumitomo Chemical Company, Limited Uracil herbicides
US20030119814A1 (en) * 2001-10-16 2003-06-26 The University Of Kansas Novel prodrugs of N-H bond-containing compounds and methods of making thereof
US20100074889A1 (en) * 2008-09-15 2010-03-25 Yao-Ling Qiu 4'-allene-substituted nucleoside derivatives

Also Published As

Publication number Publication date
WO2012047993A2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
PH12018502489A1 (en) Antiviral therapy
EA201301158A1 (en) ANTI-VIRUS COMPOUNDS
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2011123645A3 (en) Nucleoside phosphoramidates
MX2013005478A (en) Antiviral condensed heterocyclic compounds.
WO2011130557A3 (en) Phosphonates with reduced toxicity for treatment of viral infections
BR112012022311A2 (en) combination pharmaceutical agents as inhibitors of hcv replication.
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
MX2012007410A (en) Novel antiviral compounds.
TN2012000009A1 (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
UA103881C2 (en) Prevention or therapeutic treatment of infection caused by human immunodeficiency virus
MX2010008148A (en) Methods of treating viral infections.
MX2016004492A (en) Inhibitors of human immunodeficiency virus replication.
MX343505B (en) Methods and compositions for inhibiting hiv transmission.
WO2012047993A3 (en) N-hydroxypyrimidine-2,4-diones as inhibitors of hiv and hcv
WO2009021971A3 (en) Novel targets and compounds for therapeutic intervention of hiv infection
WO2011109217A3 (en) Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors
WO2008030853A3 (en) Combination therapy for human immunodeficiency virus infection
IN2013CH05288A (en)
IN2011CH03893A (en)
GB2470494A (en) Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
UA90646C2 (en) treatment OF often RECCURENT chronic herpetic infection caused by herpes virus of simple I and II type

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11831511

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11831511

Country of ref document: EP

Kind code of ref document: A2